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2Department of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis. MO, USA
Traumatic brain injury (TBI) determinate a cascade of events that rapidly lead to
neuron’s damage and death. We already reported that administration of FeTPPS,
a 5,10,15,20-tetrakis (4-sulfonatophenyl) porphyrin iron III chloride peroxynitrite
decomposition catalyst, possessed evident neuroprotective effects in a experimental
model of spinal cord damage. The present study evaluated the neuroprotective property
of FeTPPS in TBI, using a clinically validated model of TBI, the controlled cortical impact
injury (CCI). We observe that treatment with FeTPPS (30 mg/kg, i.p.) reduced: the state
of brain inflammation and the tissue hurt (histological score), myeloperoxidase activity,
nitric oxide production, glial fibrillary acidic protein (GFAP) and pro-inflammatory cytokines
expression and apoptosis process. Moreover, treatment with FeTPPS re-established
motor-cognitive function after CCI and it resulted in a reduction of lesion volumes. Our
results established that FeTPPS treatment decreases the growth of inflammatory process
and the tissue injury associated with TBI. Thus our study confirmed the neuroprotective
role of FeTPPS treatment on TBI.
Keywords: reactive oxygen species, peroxynitrite, cortical impact, inflammation, apoptosis
INTRODUCTION
Traumatic brain injury (TBI) is a common problem that lead permanent disability in patients,
particularly in the developed countries (Finnie and Blumbergs, 2002). The diagnosis of TBI is
characterized by cognitive, psychological and physical problems, closely related to the injury
(Albensi, 2001). TBI causes death and alterations of neuronal cells through primary injury that
generate molecular and cellular cascade, that determinate the secondary injury (Bramlett and
Dietrich, 2007; Werner and Engelhard, 2007). TBI damage involve metabolic changes, alterations
of the oxygenation process, neuroinflammation, axonal injury, glial and neuronal cell death
(Donkin and Vink, 2017). The current therapies are aimed exclusive to reduce the inflammatory
process and the reactive oxygen/nitrogen species (ROS/RNS) formation that induce neuronal and
cerebral blood flow alteration (Hlatky et al., 2003; Ahn et al., 2004). It has been suggested that
reactive oxygen species (ROS) generation is activated at the lesion area after TBI, leading to the
initial production of superoxide (O−2 ) and nitric oxide (NO) radicals (Schiavone and Trabace,
2016). Among oxygen radicals, superoxide anion plays a key role in the oxidative chain reaction,
producing reactive oxidant. The mitochondria are the sites of O−2 production in brain injury as well
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as under normal physiological conditions. Despite the
mitochondrial detoxification, overproduced oxygen radicals,
once uncoupled from this defense, induce oxidative stress
(Murphy, 2009; Dröse and Brandt, 2012). Mitochondria are
suggested to be the site of free radical attacks, altering ATP
generation that causes energy depletion and increases free
radicals (Murakami et al., 1998).
In activated endothelial cells, excessive O−2 react with nitric
oxide (NO) that generate peroxynitrite (ONOO−). ONOO− is
the major ROS, often considered as a RNS that is a trigger for the
advance of oxidative damage in brain (Beckman and Koppenol,
1996; Hall et al., 2010).
Many studies determined that ONOO− mediates numerous
potentially destroying chemical reactions, including lipid
peroxidation together with DNA damage (Blanchard-Fillion
et al., 2001; Alvarez and Radi, 2003; Besson et al., 2003). Also,
ONOO− suffers acid-catalyzed decomposition by different
pathways (Salvemini et al., 1998b; Groves, 1999). Diverse studies
have reported that certain water-soluble iron (III) porphyry’s
are highly active ONOO− decomposition catalysts, catalyzing
the isomerization of ONOO− almost exclusively to nitrate
producing the development of oxidizing radical species and
nontoxic nitrate anion (Misko et al., 1998; Salvemini et al.,
1998a). We examined ONOO− role in TBI using the ONOO−
decomposition catalyst 5,10,15,20-tetrakis (4-sulfonatophenyl)
porphyrin iron III chloride (FeTPPS). This compound, in
physiologically relevant conditions, catalyzes rapid isomerization
of ONOO− to nitrate (NO−3 ), moreover its cytoprotective actions
of FeTPPS were already observed in other studies (Salvemini
et al., 1998a; Jensen and Riley, 2002). In addition to the ONOO−
decomposing role, FeTPPS demonstrated a basal superoxide
dismutase effect (Khan et al., 2011). The ONOO− decomposing
effect increases significantly when both O−2 and ONOO
− are
present, thanks to the generation of a catalytic cycle (Jensen and
Riley, 2002).
Here, we would like to demonstrate, using this catalyst, that
ONOO− possess a main part in the modulation of the secondary
mechanism associated to TBI.
METHODS
Animals
Male adult CD1 mice (25–30 g, Envigo, Milan, Italy) were kept
five per cage under an invariable 12-h light/dark cycle, at room
temperature (23◦C). Food and water were accessible ad libitum.
The study was approved by the University of Messina Review
Board for the care of animals. Animal care was concordant with
Italian regulations on defense of animals used for experimental
and other scientific purposes (D.M.116192) as well as with the
EEC regulations (O. J. of E. C. L 358/1 12/18/1986).
CCI Model
TBI was induced in mice (n = 10 per group) by CCI. The mice
were anesthetized with Ketamine + Xylazine (2.6–0.16 mg/kg
of body weight, intraperitoneal i.p,) and subjected to a cortical
contusion as previous described (Logan et al., 2013). In brief,
a craniotomy was made in the right hemisphere, encompassing
bregma and lambda, and between the sagittal suture and the
coronal ridge, with a Micro motor hand piece and drill. The
resulting bone flap was removed and the craniotomy enlarged
further. A cortical contusion was produced on the exposed cortex
using the controlled impactor device Impact OneTM Stereotaxic
impactor for CCI (Leica, Milan, Italy), the impact tip was
centered and lowered over the craniotomy site until it touched
the dura mater. Then, the rod was retracted and the impact
tip was advanced farther to produce a brain injury of moderate
severity for mice (tip diameter: 4 mm; cortical contusion depth: 3
mm; impact velocity: 1.5 m/s). Immediately after injury, the skin
incision was closed with nylon sutures, and 2% lidocaine jelly was
applied to the lesion site to minimize any possible discomfort.
Experimental Groups
All animals were randomized in 4 groups:
(i) TBI + vehicle (saline): mice (n = 10 mice/group) were
subjected to CCI and vehicle was administered at 1 and 4
h after TBI,
(ii) TBI + FeTPPS group: mice (n = 10 mice/group) were
subjected to CCI and FeTPPS (30 mg/kg body weight i.p.)
was administered at 1 and 4 h after TBI,
(iii) Sham + vehicle group (saline): mice (n = 10 mice/group)
were subjected to the surgical procedures as above group
(anesthesia and craniotomy) except that the impact tip was
not applied and vehicle was administered at 1 and 4 h after
craniotomy,
(iv) Sham + FeTPPS group: mice (n = 10 mice/group) were
exposed to the surgical procedures as above group except
that the impact was not done and FeTPPS (30 mg/kg body
weight i.p.) was injected at 1 and 4 h after craniotomy.
In other set of experiments, additional animals were used for
behavioral testing: Morris water maze test (1, 2, 3, 4, and 5 days
post-TBI), Elevated PlusMaze (1, 2, 3, 6, and 10 days post-injury),
rotarod test, brain water content and swing test (at 24 h after
TBI). At 24 h, mice were anesthetized and 1-ml blood samples
were collected from mice via cardiac puncture. The samples
were centrifuged to collect plasma that stored and analyzed for
biochemical parameters.
The dose and the administration way of FeTPPS, were choose
on previous in vivo study (Genovese et al., 2007). The timing of
i.p. FeTPPS injection at 1 and 4 h after TBI has the purpose of
prevent or reduce the final neurological deficit to get the best
possible neuroprotective effect (Sullivan et al., 2011).
Behavioural Testing
Elevated Plus Maze (EPM)
Anxiety is one of the most common neurobehavioral conditions
after TBI, so anxiety deficits were evaluated using Elevated Plus
Maze system at 1, 2, 3, 6, and 10 days post-TBI and compared
with sham mice, as previously described (Pellow et al., 1985).
Rotarod Test
The rotarod treadmill (Accuscan, Inc., Columbus, OH, USA)
was used to measure motor function and balance (Brooks and
Dunnett, 2009). Each animal was placed in a neutral position on
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a cylinder (3 and 1 cm diameter for rats and mice, respectively)
then the rod was rotated with the speed accelerated linearly from
0 to 24 rpm within 60 s, and the time spent on the rotarod was
recorded automatically. The maximum score given to an animal
was fixed to 60. For testing, animals were given three trials and
the average score on these three trials was used as the individual
rotarod score.
Swing Test (EBST)
The elevated body swing test (EBST) allows to provide a motor
asymmetry parameter, involving handling the animal by its tail
and video recording the direction of the biased body swings
(Zohar et al., 2011). The EBST consisted of 20 trials with the
number of swings ipsilateral and contralateral to the injured
hemisphere recorded and expressed in percentage to determine
the biased swing activity.
Morris Water Maze Test
A spatial learning andmemory test was performed by themethod
of Morris as previous described (Maurice et al., 1994; Iancu et al.,
2005).
Measurement of Edema
At 24 h following TBI, mice were euthanized to establish brain
water content, as previously reported (Ahmad et al., 2012;
Badeli et al., 2016). The cortices were quickly removed and the
contralateral and ipsilateral hemispheres were weighed. Each
hemisphere was dried at 60◦C for 72 h, and the dry weight was
determined.
Water content was calculated in ipsilateral hemisphere as:
Water content (%) = (wet weight− dry weight)
/ wet weight× 100.
Assessment of Lesion Volume
At 24 h after injuries, mice were euthanized and brains were
frozen. The brains were sectioned in coronal sections (14 µm).
Sections were stained with haematoxylin. Area of the undamaged
and injured hemisphere was measured on each section using
image analysis software. The hemispheric volume was obtained
by summing area of each section andmultiplying it by 0.5. Lesion
volume (mm3) was expressed as difference between the uninjured
and injured hemisphere volume.
TTC Staining
The 2,3,5-triphenyltetrazolium chloride (TTC) staining
technique was used to assess infarct, as previous described
(Campolo et al., 2014). The brains were cut into five coronal
slices of 2-mm thickness. Slices were incubated in a 2% solution
of TTC at 37◦C for 30 min and immersion fixed in 10%
buffered formalin solution. TTC stains the viable brain tissue red
while infracted tissue remains unstained. For quantification of
infarcted area and volumes, the brain slices were photographed
and then image analysis was performed on a personal computer
with an image analysis software program using ImageJ. To
compensate for the effect of brain edema the corrected infarct
volume was calculated as follow:
Corrected infarct area = left hemisphere area
− (right hemisphere area− infarct area).
Values are given as mean ± SEM. The corrected total infarct
volume was calculated by summing the infarct area in each slice
and multiplying it by slice thickness (2 mm).
Histological Examination
For histopathological examination, brains were processed and
damaged neurons were counted. The histopathologic changes
of the gray matter were scored on a 6- point scale, as previous
described (Campolo et al., 2014). The scores from all the sections
from each brain were averaged to give a final score for individual
animal. All the histological studies were performed in a blinded
mode.
MPO
Myeloperoxidase activity (MPO) was determined as previously
described (Cuzzocrea et al., 2007). Brain tissue collected at the
specified time, were homogenized in a solution containing 0.5%
hexa-decyl-trimethyl-ammonium bromide dissolved in 10 mm
potassium phosphate buffer (pH 7) and centrifuged for 30 min at
20 000 g at 4◦C. An aliquot of the supernatant was then allowed
to react with a solution of tetra-methyl-benzidine (1.6 mm) and
0.1 mm H2O2. The rate of change in absorbance was measured
spectrophotometrically at 650 nm. MPO activity was expressed
in units/mg protein.
Nitrotyrosine Immunohistochemistry
A subset of mice was randomly used to evaluate protein
nitrosylation. At 24 h post-TBI, mice were sacrificed and brains
were paraffin embedded, 5-µm cross sections were cut and
fixed to slides. The sections were incubated with rabbit anti-
nitrotyrosine antibody (Upstate Biotechnology; 5 µg/mL in
2% GS/TX/BSA) and immunohistochemistry was performed as
previous described (Campolo et al., 2014).
Western Blot Analysis for IκB-α, NF-κB p65, iNOS,
p-JNK, Bax, and Bcl-2
Cytosolic and nuclear extracts were prepared as previously
described (Crupi et al., 2013). Western blot of protein lysates
from the penumbra area of injured brains was performed as
previously described (Campolo et al., 2013). The filters were
blocked with 1 PBS, 5% (w/v) nonfat dried milk (PM) for 1 h
at room temperature and subsequently probed with specific Abs
IκB-α (1/1000; Santa Cruz Biotechnology, DBA, Milan, Italy), or
anti-Bax (1/500; Santa Cruz Biotechnology), or anti-Bcl-2 (1/500;
Santa Cruz Biotechnology), or anti-iNOS (1/1000; Transduction)
or anti-NF-κB p65 (1/1000; Santa Cruz Biotechnology), or anti-
p-JNK (1/1000; Santa Cruz Biotechnology) in 1 PBS, 5% w/v
nonfat dried milk, 0.1% Tween-20 (PMT) at 4◦C, overnight.
Membranes were incubated with peroxidase-conjugated bovine
antimouse IgG secondary antibody or peroxidase-conjugated
goat anti-rabbit IgG (1/2000; Jackson ImmunoResearch, West
Grove, PA, USA) for 1 h at room temperature. To ascertain
that blots were loaded with equal amounts of proteic lysates,
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they were also incubated in the presence of the antibody against
β-actin protein (1/10,000 Sigma- Aldrich Corp.). Signals were
detected with enhanced chemiluminescence (ECL) detection
system reagent (Sigma-Aldrich, Saint Louis, Missouri, USA) and
quantified by densitometry scanning of the X-ray films with GS-
700 Imaging Densitometer (GS-700, Bio-Rad Laboratories) and a
computer program (Molecular Analyst, IBM), and standardized
for densitometry analysis to β-actin protein levels.
Measurement of Nitrite/Nitrate Production
Nitrite/nitrate production, an indicator of NO synthesis, was
measured in plasma collected 24 h after TBI as previous described
(Cuzzocrea et al., 1998). Briefly, the nitrate in the sample was
first reduced to nitrite by incubation with nitrate reductase (670
mU/ml) and β-nicotinamide adenine dinucleotide 3′-phosphate
(NADPH) at room temperature for 3 h. The total nitrite
concentration in the samples was then measured using the Griess
reaction, The optical density at 550 nm was measured using
ELISA microplate reader. Nitrite concentrations were calculated
by comparison with OD550 of standard solutions of sodium
nitrite prepared in H2O.
Immunofluorescence Staining
Sections were incubated with mouse monoclonal anti-GFAP
(1/100, v/vol Santa Cruz Biotechnology) antibody in a humidified
chamber O/N at 37 C and the detection of GFAP was obtained as
previous described (Siracusa et al., 2016). Sections were observed
and photographed using a Leica DM2000 microscope (Leica).
MATERIALS
All compounds used in this study, except where differently
specified, were purchased from Sigma-Aldrich Company
Ltd. (Poole, Dorset, UK). All solutions used for in vivo
administrations were made using nonpyrogenic saline (0.9%
wt/vol NaCl; Baxter Healthcare Ltd., Thetford, Norfolk, UK).
STATISTICS
Data were analyzed with Graphpad PRISM V (Graphpad
Software Inc., La Jolla, CA). Swing activity, time on platform,
time spent on open armentries, and escape latency results
were analyzed using two factor repeated measures analysis of
variance (RM ANOVA, group × time). Physiological variables,
time in the target quadrant, cross platform, edema, infarct
area, lesion volume, MPO, NO, and densitometric analysis data
were analyzed by ANOVA followed by a Bonferroni post-hoc
test for multiple comparisons. For one way ANOVA statistic
test, a single “F” value indicated as variation between sample
FIGURE 1 | Effect of FeTPPS on behavioral function. FeTPPS accelerated recovery, getting an improved behavioral function. At 24 h after TBI, significant
impairments were observed in motor deficits, as revealed by biased swing activity (A) and lower time of permanence on rotarod (B). Instead, treatment with FeTPPS
1h post-trauma significantly improved motor function, as observed in EBST (A) and in rotarod task (B). Moreover, FeTPPS ameliorated cognitive function (C) as
evaluated by EPM test at 1, 2, 3, 6, and 10 days after TBI. Data are expressed as mean ± SEM from N = 10 male CD mice for each group. A p-value of less than
0.05 was considered significant. **p < 0.01 and ***p < 0.001 vs. Sham + veh; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. TBI + veh.
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means/variation within the samples was shown. Histological
score and % total tissue area were analyzed by t-test. For
all comparisons, p < 0.05 was considered significant. In the
experiments involving histology or immunohistochemistry, the
figures shown are representative of at least three experiments
performed on different experimental days on the tissue sections
collected from all the animals in each group.
RESULTS
Behavioral Recovery and Improvement
Mice injured showed behavioral deficits. Two different tests,
the EBST and the Rotarod test, that are the most sensitive
vestibulomotor tests (Iancu et al., 2005), were used to examine the
relationship between neurological deficits in the setting of TBI.
CCI-injured mice showed a series of impairments in locomotors
tasks as observed in Figure 1.
First of all, to evaluate motor function impairment mice were
subjected to the elevated body swing test (EBST), 24 h after TBI.
Sham group had no apparent bias in swing behavior (Figure 1A),
whereas FeTPPS treatment significantly ameliorated influence on
the swing bias (Figure 1A) compared to TBI group (Figure 1A).
Moreover, to test overall balance, motor coordination, and motor
learning we performed Rotarod test. The sham-operated mice
were not observed to slip from the rod at any time (Figure 1B),
whereas injured mice found it difficult to walk precisely on the
rod, tending to lose their balance (Figure 1B). FeTTPS treatment
improve the performance of mice that remained on the rotor for
longer periods (Figure 1B).
Subsequently, to assess the anxiety, a decisive component of
behavioral change after brain injury, CCI injured animals were
subjected to the Elevated Plus Maze (EPM) at 1, 2, 3, 6, and 10
days; also, mice were treated with FeTPPS every day, observing an
improved latency compared to TBI+ vehicle group (Figure 1C).
Effects of FeTPPS on the Performance
after TBI in Morris Water Maze Test (MWM)
In the MWM test, the TBI group exhibited longer escape
latency on day 1, 2,3, 4, and 5 (Figure 2A), compared with
the sham group and sham+ FeTPPS. However, the FeTPPS
treatment significantly ameliorated the effects of TBI on escape
latency. Memory retention of the podium position was assessed
in the spatial probe test performed on the day following the
place navigation test; TBI mice spent minor time in the target
quadrant respect to control groups, although the difference in
cross platform times was not markedly different. The shorter
swimming time in the target quadrant induced by TBI was
significantly restored by FeTPPS (30 mg/Kg) (Figures 2A–C).
No significant difference was noted among all the groups in
swimming speed throughout the test (data were not shown).
FIGURE 2 | Effect of FeTPPS treatment on the performance of Morris Water Maze (MWM) in mice after TBI. The MWM was utilized to analyze spatial
learning and memory to allow for recovery of motor deficits. Escape latency (A), time in the target quadrant (B), and cross platform times (C) were measured. Data are
means ± SEM of 10 animals for each group,*p < 0.05, **p < 0.01, and ***p < 0.001 vs. Sham + veh; #p < 0.05 vs. TBI + veh.
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Decrement of Edema and Brain Infarctions
following Trauma
Brain water content is a sensitive measure scoring pathology
associated with endothelial cell activation and dysfunction.
The brain water content was significantly different between
all groups with levels substantially more high in TBI-injured
mice compared to sham group, as shown in Figure 3A.
FeTPPS treatment at 24 h post-injury significantly reduced
the increased water content in the ipsilateral brain, caused by
TBI. To appraise the effects of FeTPPS on brain infarctions,
we performed the 2,3,5-triphenyltetrazolium chloride (TTC)
staining (Figure 3B). The infarct area (Figure 3C) and infarct
volume (Figures 3D,E) were significantly reduced after treatment
with FeTPPS (Figures 3C,D).
Histological Examination
Histological examination of the brain from TBI animals, at
24 h post-damage, showed significant tissue disorganization,
inflammation in the perilesional area and white matter alteration
(Figure 4c, histological score Figure 4e) compared to control
(Figure 4a, histological score Figure 4e) and compared to sham
animals that received FeTTPs (Figure 4b). We showed that
the treatment with FeTPPS (30 mg/kg) notably reduced the
degree of brain injury (Figure 4d, histological score Figure 4e).
In addition, the above-mentioned histological pattern of TBI
seemed to be associate with the incursion of leukocytes into
the brain. Therefore, we analyzed the effects of FeTPPS on
neutrophilic infiltration by measuring brain MPO activity and
we observed that MPO activity was considerably elevated in
the brain of mice at 24 h after trauma compared with sham-
operated animals (Figure 4f). Treatment with FeTPPS attenuated
neutrophilic infiltration into the brain at 24 h after injury.
TBI Effects of FeTPPS on Nitrotyrosine
Formation and NO Production
To verify the localization of different reactive nitrogen
species produced during TBI, nitrotyrosine was measured
by immunohistochemical analysis, 24 h after brain damage.
Brain sections from control mice (Figure 5a, densitometry
analysis Figure 5e) and FeTPPS-treated animals (Figure 5b,
densitometry analysis Figure 5e) did not stain for nitrotyrosine,
while brain sections obtained from injured mice exhibited a
positive staining for nitrotyrosine (Figure 5c, densitometry
analysis Figure 5e), localized in inflammatory tissues. Treatment
with FeTTPs significantly reduce the positive staining for
nitrotyrosine (Figure 5d). To determine the role NO produced
during TBI, inducible nitric oxide synthase (iNOS) expression
was evaluated by western blot. An important increase in iNOS
expression was observed in the brain from TBI- injured mice
(Figure 5f). On the contrary, FeTPPS treatment prevented
the TBI-induced iNOS expression (Figure 5f). Moreover, the
analysis conducted on the plasma of all animals showed that in
the mice subjected to TBI there was a significant concentration
in NO2 compared to sham mice. The increase in plasma NO2
FIGURE 3 | FeTPPS reduces brain edema and infarctions following TBI. At 24 h after trauma were observed increased levels of water content in the TBI brain
(A), while the treatment with FeTPPS decreased the brain edema (A). Brain sections (2 mm thick) were stained with TTC at 24 h post-trauma (B) to show significant
reduction in infarct area (C) and volume (D,E). Lesion volume measured by hematoxylin after injury was significantly larger in CCI group vs. sham group (E). *p < 0.05,
and ***p < 0.001 vs. Sham + veh; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. TBI + veh.
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FIGURE 4 | Severity of Brain damage on histological alterations and MPO activity. FeTPPS reduces the severity of brain trauma. No alteration in brain tissues
from control mice (a, histological score e) and sham + FeTPPS (b, histological score e) was evident. On the contrary, the low-magnification images of damaged brain
showed tissue disorganization and inflammation in the perilesional area at 24 h after injury (c, histological score e). A considerable protection from the TBI was
apparent in the tissue collected from FeTPPS treated mice (d, histological score e). Moreover, MPO activity was significantly increased in the brain (f) from
TBI-induced mice in comparison with sham mice. FeTPPS treatment significantly reduced the TBI-induced increase in myeloperoxidase activity. Data are means ±
SEM of 10 mice for each group, *p < 0.05 vs. Sham + veh; #p < 0.05 vs. TBI + veh.
levels was significantly reduced in animals treated with FeTPPS
(Figure 5g).
Effect of FeTTPS on GFAP Expression
The relative fluorescence intensity of GFAP was evaluated in
brain tissues. In the injured brains, a major expression for
GFAP was observed in the TBI (Figure 6d); astrocytes activation
was significantly lower in FeTPPS vs. TBI groups (Figure 6g).
GFAP levels were basal in sham group (Figure 6a). The red
arrow indicates the localization of GFAP (Figures 6c,f,i) and
DAPI, staining assay was performed to reveal the cell viability
(Figures 6b,e,h). Moreover GFAP expression was evaluated by
western blot analysis. We clearly demonstrated that FeTPPS
treatment reduces GFAP expression, that was significantly
increased after TBI (Figure 6j).
Effects of FeTPPS on NF-κB p65 Pathway
We evaluated inhibitor of kappa B (IkB-α) degradation, nuclear
factor kappa B (NF-κBp65) translocation and p-JNK expression
by western blot analysis to investigate the cellular mechanisms
whereby treatment with FeTPPS is protective in TBI. Basal
expression of IkB-α was detected in brain homogenates
from sham-operated mice, whereas IkB-α were substantially
degradated in brain tissue collected from TBI mice (Figure 7A).
FeTPPS treatment impeded TBI-induced degradation of IkB-α
(Figure 7A). Moreover, NF-κB p65 translocation in the brain
nuclear fractions was also considerably increased 24 h after
TBI respect to control mice (Figure 7B). FeTPPS treatment
appreciably reduced the expression of NF-κB p65 (Figure 7B).
Effects of FeTPPS on MAPK Expression
At 24 h after TBI, the expression of MAPK, such as p-ERK,
pP38, and p-JNK in brain homogenates were also investigated.
Basal expression of MAPKs were detected in brain homogenates
from sham-operated mice, whereas MAPKs expression were
considerably increased in TBI mice (Figures 8A–C, respectively).
FeTPPS treatment prevented TBI-induced MAPKs increase
expression (Figures 8A–C, respectively).
Effects of FeTPPS on Apoptosis
To investigate if brain trauma was correlated to apoptosis,
the appearance of proteic effectors of canonical mitochondrial
apoptosis, such as pro-apoptotic (Bax) proteins and anti-
apoptotic (Bcl-2) proteins, was investigated by western blot
analysis. Bax levels were appreciably increased in the brain from
mice subjected to TBI (Figure 8A). On the contrary, FeTPPS
treatment banned TBI-induced Bax expression (Figure 9A).
Moreover, in the brain extract from sham mice a basal level
of Bcl-2 was detected (Figure 8B). In TBI-induced mice, Bcl-2
expression was significantly reduced (Figure 9B), while FeTPPS
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FIGURE 5 | Effects of FeTPPS on NO production after TBI. Brain tissue section from sham mice (a) and sham + FeTPPS (b) haven’t shown any positive staining
for nitrotyrosine. Sections from TBI-injured mice demonstrated positive staining for nitrotyrosine (c), notably reduced by FeTPPS treatment (d). In addition, iNOS
expression and plasma levels of nitrite/nitrate (NO2) were also performed. At 24 h after trauma, an important increase in the iNOS expression (f) and plasma levels
NO2- were observed in brain (g) compared with the sham mice. FeTPPS treatment significantly reduced iNOS expression and NO2 plasma levels. β-actin was used
as internal control. A representative blot of lysates obtained from each group is shown, and densitometry analysis of all animals is reported (N = 10 mice from each
group). ***p < 0.001 vs. Sham + veh; #p < 0.05, ##p < 0.01, and ###p < 0.001 vs. TBI + veh; F 102.8.
administration determined an increase in Bcl-2 expression
(Figure 9B).
DISCUSSION
TBI is a major problems that aﬄict the society with an
increased incidence in young adults (Maas et al., 2008). Multiple
factors affected the outcome of brain injury and currently,
there aren’t neuroprotective treatment strategies to get better
neurological outcome after trauma. The use of in vivo models
for TBI enhanced the comprehension of TBI pathophysiology,
in particular CCI models result in an ipsilateral injury that
reproduce damages similar to that observed in humans, such
as cortical contusion, edema, elevated intracerebral pressure,
subarachnoid hemorrhage, decreased cerebral blood flow, neuro-
endocrine and metabolic dysfunctions (Morales et al., 2005).
Moreover, CCI model, reproduces numerous features of brain
injuries, including neuron less, motor and cognitive deficits
(Colicos et al., 1996; Hoffman et al., 2008; Kline et al., 2008).
The gravity of injury can be controlled by changing velocity
and profundity of impact and the size of the impactor tip
(Dixon et al., 1991). It is accepted that very severe trauma
involves numerous pathways. Following trauma it is observed
a dramatic breakdown of membrane and DNA, caused by
the increased action of free radical endogenous scavenging
molecules, that finally determined cell death (Bains and Hall,
2012).
It is known that TBI elicits behavioral function impairment,
probably due to the over activation of glutamate receptors in
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FIGURE 6 | FeTPPS reduces the GFAP immunoreactivity following TBI at 24 h post-injury. Compared to the GFAP immunoreactivity in unaltered control
tissue, significantly increased number of GFAP positive astroglial cells were detected in TBI mice (d). The effect was attenuated by FeTPPS treatment (g). Fluorescent
photomicrographs from brain tissue stained with DAPI (blue; b,e,h), GFAP (green; a,d,g), and a merged image of DAPI and GFAP (c,f,i) were shown. Western blot
analysis demonstrated that FeTTPS reduced GFAP expression (j). *p < 0.05 vs. Sham + veh;. #p < 0.05 vs. TBI + veh. F 13.01.
FIGURE 7 | Effect of FeTPPS on IkB-a, NF-κB p65. IkB-α was significantly degraded in brain tissues obtained from TBI-induced mice (A). FeTPPS treatment mice
prevented TBI-induced IkB-α degradation (A). Nuclear NF-κB p65 translocation was significantly increased in brain nuclear fractions from TBI-induced mice compared
with FeTPPS treated mice (B). A representative blot of lysates obtained from five animals per group is shown, and densitometry analysis of all animals is reported.
***p < 0.001 vs. Sham + veh;#p < 0.05 vs. TBI + veh; F-value for IkB-α 33.81; F-value for NF-κB p65 58.21.
the hippocampus that confounds rehabilitation and concurs to
a poor quality of life. The neurological deficit was evaluated
with two different tests: rotarod test that revealed an increase
performance of mice treated with FeTTPS compared to TBI
animals; EPM showed increased anxiety-like behavior in mice
subject to TBI and this behavioral phenotype was reversed by
FeTTPS administration. Improvement of learning and memory
remains a significant goal of TBI research; unluckily, up to day
there is no promising therapies for TBI.
The role of reactive-oxygen-induced oxidative injury in TBI
was strongly observed in various studies (Benuck et al., 1992;
Deng et al., 2007), that demonstrated that ROS production
and inflammatory process continues for at least 1 h after
damage (Cobbs et al., 1997). Through the reactive-oxygen-
induced oxidative damage ONOO−plays important roles, it is
very reactive toward biological molecules (Salvemini et al., 2006)
and sufficient stable to cross cell and to contact target cells prior
to becoming protonated (Crow and Beckman, 1995). A better
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FIGURE 8 | Effect of FeTPPS on MAPKs expression. A significant increase in p-ERK (A), pP38 (B), and p-JNK (C) were observed in brain tissues obtained from
TBI mice compared with sham animals: FeTPPS restored the expression of p-ERK (A), pP38 (B), and p-JNK (C). ***p < 0.001 vs. Sham + veh; **p < 0.01 vs. Sham
+ veh; ##p < 0.01 vs. TBI + veh. #p < 0.05 vs. TBI + veh. F-value for p-Erk 85.83; F-value for p-P38 15.47; F-value for p-JNK 38.96.
FIGURE 9 | Effects of FeTPPS on apoptotic proteins in brain tissue. Western blot data detected a significant increase in Bax expression (A) in the brain tissues
caused by TBI, while FeTPPS treatment significantly reduced the proapoptotic Bax expression in the brain at 24 h after injury. Moreover, Bcl-2 levels were significantly
lowered in TBI-injured mice at 24 h (B), but significantly restored by FeTPPS treatment. **p < 0.01 vs. Sham + veh; #p < 0.05 vs. TBI + veh. F-value for Bax 45.85;
F-value for Bcl2 26.88.
clarification of the function of ONOO− in human disease should
provide a great contribution in the design of balanced therapies
for pharmacological intervention. To this purpose, FeTPPS with
its properties, could be represent a new therapeutic approach
for treat TBI. This consideration is based on a previous study
in which FeTMPS, another ONOO− decomposition catalyst,
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decreased the expression of pro-inflammatory cytokines in a
model of I/R of the gut (Cuzzocrea et al., 2000).
Moreover, we already demonstrated that FeTSPP possess anti-
inflammatory and neuroprotective effects in an another disease
in which ONOO− is implicated in a generation of secondary
cytotoxic neuronal damage during spinal cord injury (SCI)
(Genovese et al., 2007).
We clearly demonstrated that FeTSPP treatment reduced the
development of inflammation and tissue injury associated with
spinal cord trauma similarly to a well-known anti-inflammatory
agent that were used as positive control.
Nevertheless implications for the contribution of ONOO− to
disease are based principally on nitrotyrosine formation, that is
marker of “footprint” ONOO− and nitrosative stress. Thus, in
this study we have observed that FeTPPS considerably reduced
nitrotyrosine formation.
Moreover NO in turn control GFAP expression in astrocytes
(Brahmachari et al., 2006). Though the astrocyte activation
implies the production of different neurotrophins for neuronal
survival, at the same time it is implicates in the inflammatory
process, provoking brain and neuronal damage (Tani et al., 1996).
Thus, here we also evaluated by immunofluorescence analysis
the expression of GFAP, as astrocyte activation marker, and the
results obtained demonstrated a high expression of GFAP after
TBI compared with FeTPPS-treated mice.
The increase in oxidative stress has, as the consequence, the
activation and inactivation of redox-sensitive proteins (Bowie
and O’Neill, 2000). Recent studies propose that the activation of
NF-κB may also be controlled by an oxidant/antioxidant balance
(Haddad, 2002). NF-κB is normally located in the cytoplasm,
bound to regulatory protein IκBα. Pro-inflammatory stimuli
induce phosphorylation of IκB by the enzyme IκB kinase (Bowie
and O’Neill, 2000) with the release of NF-κB, which is then
free to translocate in the nucleus. Thus in the present study
we demonstrated that FeTPPS inhibited the IκB-α degradation
and NF-κB translocation demonstrating that ONOO−also
regulated the equilibrium between proinflammatory and
prosurvival roles of NF-κB. Moreover, NF-κB control the
expression of inflammatory protein, such as iNOS, TNF-α
and IL-1β (Salvemini and Cuzzocrea, 2002). Moreover, the
inflammatory process that follow TBI, is correlated with
lipid peroxidation and neutrophil accumulation in the brain
(Morganti-Kossmann et al., 2002; Bao et al., 2012). Thus, here
we observed by MPO activity that administration of FeTTPS
significantly reduced the neutrophilic accumulation caused
by TBI.
Moreover, iNOS production as well as plasma NO levels,
evaluated as NO2/NO3, have been also involved in TBI (Orihara
et al., 2001). iNOS expression was observed near inflammatory
areas mainly in neutrophils/macrophages, while iNOS inhibition
was protective against damage in TBI mice models (Khan
et al., 2004). In the present study we demonstrated that
FeTPPS treatment was able also to inhibit iNOS expression
after injury, demonstrating the benefical role of FeTPPS
against iNOS-mediated damage. Furthermore, during TBI the
oxidative stress activate an important intracellular transduction
system the Mitogen activated protein kinases (MAPK) pathway,
specifically JNK, that are activated in response of oxidative
stress, environmental stress and toxic insults, during pathological
conditions (Benhar et al., 2001; LaChapelle et al., 2007). Thus
in the present study we observed that MAPKs levels were
significantly increased after TBI, whereas FeTPPS treatment
prevented TBI-induced MAPPKs activation.
Apoptosis is another important regulator of brain injury
controlling the degeneration of different cell types and involving
oligodendrocytes and microglia (Mandai et al., 1997). In the
present work, we studied the apoptotic transcriptional changes,
through the pro-apoptotic Bax and the anti-apoptotic Bcl-2
proteins; we cleraly observed that FeTPPS treatment considerably
reduced Bax expression, restoring the basal levels of Bcl-2.
In conclusion, we demonstrated that peroxynitrite production
and inflammatory process are associated with brain damage
aroused by trauma, contributing to secondary brain damage
and progressive neuronal loss. Here, we report evidence
that support the dual, the beneficial or the deleterious role
of neuroinflammation after traumatic brain injury. Thus,
the ONOO− decomposition catalysts represent an innovative
approach to supervise the pathological sequelae associated with
TBI. To better understand the key role that peroxynitrite plays in
the progress of inflammatory diseases, such as TBI, these catalysts
were used as pharmacological tools in vivo models of human
disease. Successively, this should provide more helpful treatment
strategies for diseases in the clinic.
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